A five-year study involving 214 children born to healthy, non-smoking Caucasian women in Krakow, Poland, has found that those prenatally exposed to high levels of polycyclic aromatic hydrocarbons (PAHs) had a significant reduction in scores on a standardized test of reasoning ability and intelligence at age 5 (an estimated average decrease of 3.8 IQ points). The mothers wore small backpack personal air monitors for 48 hours during pregnancy to estimate their babies' PAH exposure.
Latest Research News
The role of the catechol-O-methyltransferase (COMT) gene in cognitive function has been the subject of some debate. The gene, which affects dopamine, comes in two flavors: Val and Met. One recent study found no difference between healthy carriers of these two gene variants in terms of cognitive performance, but did find differences in terms of neural activity. Another found that, although the gene did not affect Alzheimer’s risk in its own, it acted synergistically with the Alzheimer’s gene variant to do so.
A study involving 236 persons with multiple sclerosis has found that only 7% of those with secondary-progressive MS showed sufficient vitamin D in their blood, compared to 18.3% of patients with the less severe relapsing-remitting type, and that higher levels of vitamin D3 and its byproducts were associated with better scores on cognitive tests (especially reasoning and planning), and less brain atrophy and fewer brain lesions. Lower-than-normal vitamin D status is known to be associated with a higher risk of developing MS
Previous research has found that unexplained weight loss is an early sign of Alzheimer's. Now a study involving 140 older adults (60+), of whom half had early-stage Alzheimer's disease, has revealed that it is not the overall weight or fat levels that are important, but the loss of lean mass (weight of an individual's bones, muscles and organs without body fat). This directly correlated with reductions in the volume of the whole brain and of white matter only, along with declines in cognitive performance.
A study involving five patients with severe amnesia due to damage in the hippocampus, resulting in a condition comparable to Alzheimer's, has found that memory tests given 5-10 minutes after sad and happy film clips showed little (if any) memory of the details, but the generated emotion lasted for 20 to 30 minutes afterward. Interestingly, normal controls also felt happy for about the same length of time, but the impact of sad scenes was shorter. The findings challenge the idea that by minimizing a specific memory of past trauma, associated sadness will also decrease.
The largest ever trial of fish oil supplements has found no evidence that they offer benefits for cognitive function in older people. The British study enrolled 867 participants aged 70-80 years, and lasted two years. After two years, those receiving fish oil capsules had significantly higher levels of omega-3 fatty acids in their blood than those receiving placebo capsules. However, cognitive function did not decline in either group over the period. The researchers caution that it may be that more time is needed for benefits to show.
The Phase II clinical trial of a treatment using naturally occurring antibodies (IGIV) has achieved significantly lower rates of ventricular enlargement (6.7% vs 12.7% per year) and less whole-brain atrophy (1.6% vs 2.2% per year) than control subjects who initially received placebo. The trial ran for 18 months and involved 24 patients with mild to moderate Alzheimer's disease, of whom 16 received IGIV once or twice a month for the whole period, and 8 received a placebo for the first 6 months.
An intriguing set of experiments showing how you can improve perception by manipulating mindset found significantly improved vision when:
As we all know, being interrupted during a task greatly increases the chance we’ll go off-kilter (I discuss the worst circumstances and how you can minimize the risk of mistakes in my book Planning to remember). Medication errors occur as often as once per patient per day in some settings, and around one-third of harmful medication errors are thought to occur during medication administration.
Another gene has been identified that appears to increase risk of Alzheimer’s. The gene, MTHFD1L, is located on chromosome six. Comparison of the genomes of 2,269 people with late-onset Alzheimer's disease and 3,107 people without the disease found those with a particular variation in this gene were almost twice as likely to develop Alzheimer's disease as those people without the variation. The gene is involved in influencing the body's levels of homocysteine (high levels are known to be a strong risk factor), and have also been implicated in coronary artery disease.